A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis

Inclusion Criteria: * Male or female 18 to 70 years of age. * Plaque-type psoriasis with two lesions of similar size and have an identical score of at least 6 but no more than 8 on the sum of the individual components of the Severity of Psoriasis Area Severity Index (PASI) at the Target Lesion scale. * Male or non-pregnant, non-lactating females. * Signed informed consent. Exclusion Criteria: * Subjects who have extensive, and/or 'inverse', and/or exfoliative psoriasis. * Subjects who have taken any systemic treatment for psoriasis within the 4 weeks prior to baseline. * Prior or concomitant use of topical treatments for psoriasis to within 10 cm of the target lesion within the 4 weeks prior to baseline. * Use of Enbrel within the 4 weeks prior to baseline. * Psoralen \& ultraviolet A therapy (PUVA) or the use of ultraviolet B (UVB) therapy and/or excessive or prolonged exposure to ultraviolet light within the 4 weeks prior to baseline. * Use of Humira or Remicade within the 3 months prior to baseline. * Use of Stelara within the 6 months prior to baseline. * Subjects who have taken oral retinoids for psoriasis within the 6 months prior to baseline. * Subjects who have poor skin condition within 5 cm of the target lesion. * Subjects who are current drug or alcohol abusers; have a history of immunodeficiency disease or are a poor medical risk because of other systemic diseases or active uncontrolled infections. * Subjects with an unstable medical condition or a medical condition not adequately controlled with standard medical therapy. * Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days * Subjects who have a clinically significant laboratory value at screening.